相关论文: Basal Glucose Control in Type 1 Diabetes using Dee…
This paper explores the application of reinforcement learning to optimize the parameters of a Type-1 Takagi-Sugeno fuzzy controller, designed to operate as an artificial pancreas for Type 1 diabetes. The primary challenge in diabetes…
Type 1 Diabetes (T1D) affects millions worldwide, requiring continuous monitoring to prevent severe hypo- and hyperglycemic events. While continuous glucose monitoring has improved blood glucose management, deploying predictive models on…
Control of blood glucose is essential for diabetes management. Current digital therapeutic approaches for subjects with Type 1 diabetes mellitus (T1DM) such as the artificial pancreas and insulin bolus calculators leverage machine learning…
Around a third of type 2 diabetes patients (T2D) are escalated to basal insulin injections. Basal insulin dose is titrated to achieve a tight glycemic target without undue hypoglycemic risk. In the standard of care (SoC), titration is based…
Simulating glucose dynamics in individuals with type 1 diabetes (T1D) is critical for developing personalized treatments and supporting data-driven clinical decisions. Existing models often miss key physiological aspects and are difficult…
While the Artificial Pancreas is effective in regulating the blood glucose in the safe range of 70-180 mg/dl in type 1 diabetic patients, the high intra-patient variability, as well as exogenous meal disturbances, poses a serious challenge.…
The Glucose-Insulin-Glucagon nonlinear model [1-4] accurately describes how the body responds to exogenously supplied insulin and glucagon in patients affected by Type I diabetes. Based on this model, we design infusion rates of either…
Type 1 diabetes mellitus (T1D) is characterized by insulin deficiency and blood glucose (BG) control issues. The state-of-the-art solution for continuous BG control is reinforcement learning (RL), where an agent can dynamically adjust…
Diabetes mellitus is a global health crisis characterized by poor blood sugar regulation, impacting millions of people worldwide and leading to severe complications and mortality. Although Type 1 Diabetes Mellitus (T1DM) has a lower number…
Background and objective: Hybrid automated insulin delivery (hAID) systems represent the most advanced therapy for type 1 diabetes (T1D). Current systems rely on linear or linearized models of glucose homeostasis, which may compromise…
In type 2 diabetes (T2D) treatment, finding a safe and effective basal insulin dose is a challenge. The dose-response is highly individual and to ensure safety, people with T2D titrate by slowly increasing the daily insulin dose to meet…
Objective: The artificial pancreas (AP) has shown promising potential in achieving closed-loop glucose control for individuals with type 1 diabetes mellitus (T1DM). However, designing an effective control policy for the AP remains…
Patients with Type I Diabetes (T1D) must take insulin injections to prevent the serious long term effects of hyperglycemia - high blood glucose (BG). Patients must also be careful not to inject too much insulin because this could induce…
People living with Type 1 Diabetes (T1D) lose the ability to produce insulin naturally. To compensate, they inject synthetic insulin. One common way to inject insulin is through automated insulin delivery systems, which use sensors to…
Comorbid chronic conditions are common among people with type 2 diabetes. We developed an Artificial Intelligence algorithm, based on Reinforcement Learning (RL), for personalized diabetes and multi-morbidity management with strong…
We present a fully closed-loop design for an artificial pancreas (AP) which regulates the delivery of insulin for the control of Type I diabetes. Our AP controller operates in a fully automated fashion, without requiring any manual…
High quality real world datasets are essential for advancing data driven approaches in type 1 diabetes (T1D) management, including personalized therapy design, digital twin systems, and glucose prediction models. However, progress in this…
Type 1 Diabetes (T1D) is an autoimmune disease leading to insulin insufficiency. Thus, patients require lifelong insulin therapy, which has a side effect of hypoglycemia. Hypoglycemia is a critical state of decreased blood glucose levels…
People with diabetes need insulin delivery to effectively manage their blood glucose levels, especially after meals, because their bodies either do not produce enough insulin or cannot fully utilize it. Accurate insulin delivery starts with…
Type 1 diabetes (T1D) management can be significantly enhanced through the use of predictive machine learning (ML) algorithms, which can mitigate the risk of adverse events like hypoglycemia. Hypoglycemia, characterized by blood glucose…